Center for Infectious Disease Dynamics, Departments of Biology and Entomology, Pennsylvania State University, University Park, Pennsylvania, United States of America.
PLoS Pathog. 2013 Sep;9(9):e1003578. doi: 10.1371/journal.ppat.1003578. Epub 2013 Sep 12.
Drug resistant pathogens are one of the key public health challenges of the 21st century. There is a widespread belief that resistance is best managed by using drugs to rapidly eliminate target pathogens from patients so as to minimize the probability that pathogens acquire resistance de novo. Yet strong drug pressure imposes intense selection in favor of resistance through alleviation of competition with wild-type populations. Aggressive chemotherapy thus generates opposing evolutionary forces which together determine the rate of drug resistance emergence. Identifying treatment regimens which best retard resistance evolution while maximizing health gains and minimizing disease transmission requires empirical analysis of resistance evolution in vivo in conjunction with measures of clinical outcomes and infectiousness. Using rodent malaria in laboratory mice, we found that less aggressive chemotherapeutic regimens substantially reduced the probability of onward transmission of resistance (by >150-fold), without compromising health outcomes. Our experiments suggest that there may be cases where resistance evolution can be managed more effectively with treatment regimens other than those which reduce pathogen burdens as fast as possible.
耐药病原体是 21 世纪主要的公共卫生挑战之一。人们普遍认为,通过药物快速消除患者体内的目标病原体,耐药性是最好的管理方式,以最大程度地减少病原体新出现耐药性的可能性。然而,强烈的药物压力通过减轻与野生型种群的竞争,强烈地选择耐药性。因此,激进的化疗会产生相反的进化力量,共同决定耐药性出现的速度。确定既能最大程度地延缓耐药性进化,又能最大程度地提高健康收益和降低疾病传播的治疗方案,需要结合临床结果和传染性的衡量,对体内耐药性进化进行实证分析。我们利用实验室小鼠中的鼠疟原虫发现,不那么激进的化疗方案可大大降低耐药性传播的可能性(降低 150 多倍),而不会影响健康结果。我们的实验表明,在某些情况下,通过治疗方案管理耐药性进化可能比通过尽快降低病原体负担更有效。